Health Ministry Therapy: Restricts Autism Treatment Strictly to Clinical Trials

• by Akanksha Mishra
• 2026-09-18 16:50:00

The Union Ministry of Health and Family Welfare has issued a comprehensive regulatory advisory restricting the therapeutic application of stem cell interventions across healthcare facilities nationwide. Formally circulated on September 16, 2026, to all States and Union Territories implementing the Clinical Establishments (Registration and Regulation) Act of 2010, the directives mandate that stem cell therapies can strictly be offered as standard medical care only for established disease conditions officially approved by the Ministry. Arriving in the wake of the landmark January 30, 2026 Supreme Court ruling in Yash Charitable Trust & Ors. v. Union of India, the directive aims to dismantle unverified commercial healthcare claims, ensuring that unproven cellular therapies are completely eliminated from routine clinical packages and aggressive direct-to-consumer medical marketing.

Clear Distinction Between Established Hematologic Transplants and Experimental Cellular Medicine

Weighing in on the national advisory, Dr. Prashant Mehta, Program Head of Bone Marrow Transplant (BMT), CAR-T & Cellular Therapy at Amrita Hospital, Faridabad, emphasized that stem cells are not inherently unproven, noting that hematopoietic stem cell transplantation remains a globally recognized standard of care for severe hematologic malignancies and bone marrow disorders. However, clinical and ethical concerns escalate when clinics package experimental cellular procedures as cures for complex neurological conditions without empirical validation. The Health Ministry’s decisive action creates a clear operational boundary between evidence-backed transplant procedures and speculative commercial offerings, shielding patients and their families from exploitation while providing a safe, ethical foundation for ongoing medical research.

Insufficient Scientific Evidence for Autism Spectrum Disorder: Clinical Trial Mandate Enforced

The advisory takes a firm stance against using stem cell procedures for Autism Spectrum Disorder (ASD), ruling that any therapeutic administration of cellular materials for autism must remain strictly confined to duly regulated and ethically approved clinical trials. Highlighting the clinical rationale, Dr. Mehta cited recent randomized placebo-controlled trials—including studies with 32 and 34 pediatric subjects—which established initial procedural feasibility in small cohorts but failed to deliver definitive clinical efficacy or long-term safety data. Systematic reviews continue to identify glaring methodological weaknesses, including tiny sample sizes, fluctuating cell dosages, varied administration protocols, and short follow-up periods. Reaffirming that therapeutic promise should never be mistaken for clinical proof, the Ministry insists that scientific rigor, voluntary informed consent, and patient protection must take precedence over commercialized therapies.

Previous Post

Beyond Physical Tiredness: Why Your Brain Feels Drained and How to Recharge

Next Post

'Vision for Every Indian': Free Eye Screenings and Cataract Surgeries Across 800 Districts Announced